Market Alert: Trump Revives Trade War Playbook with Tariff Threats
Neurizon Therapeutics (ASX: NUZ) has developed a new oral liquid formulation of its lead drug candidate, NUZ-001, aimed at improving access and treatment experience for patients with Amyotrophic Lateral Sclerosis (ALS). This patient-centric advancement is particularly beneficial for individuals with bulbar onset or swallowing difficulties, enabling easier administration and continuity of therapy through various stages of ALS progression.
The formulation supports Neurizon’s long-term strategy to evolve NUZ-001 into a scalable treatment platform, enhancing both patient outcomes and commercial potential. Designed based on patient and caregiver feedback, it allows for flexible dosing and administration via feeding tubes. The liquid form will be included in the company’s ongoing clinical program, with a human bioequivalence study set for H1 CY 2026. This development underscores Neurizon’s commitment to delivering accessible, inclusive treatments tailored to the needs of people affected by neurodegenerative diseases like ALS.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
